Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
HOUSTON, TEXAS, Feb. 08, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq:NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device, has been granted regulatory approval by the Sultanate of Oman’s Ministry of Health.
Related news for (NXL)
- MoBot alert highlights: NASDAQ: HTCR, NASDAQ: CGTX, NASDAQ: NXL, NASDAQ: ANTE, NASDAQ: MODV (08/22/25 12:00 PM)
- MoBot alert highlights: NASDAQ: NXL, NASDAQ: ANTE, NASDAQ: MODV, NASDAQ: EQ, NASDAQ: IPA (08/22/25 11:00 AM)
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
- Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
- Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering